北大医药(000788) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was approximately ¥571.62 million, representing a 2.81% increase compared to ¥555.99 million in the same period last year[5]. - Net profit attributable to shareholders decreased by 10.45% to approximately ¥14.40 million from ¥15.94 million year-on-year[5]. - Basic earnings per share decreased by 10.37% to ¥0.0242 from ¥0.0267 in the same period last year[5]. - Total operating revenue for the current period reached ¥1,655,471,575.84, an increase of 6.36% compared to ¥1,556,984,364.28 in the previous period[38]. - Operating profit for the current period was ¥65,000,552.83, compared to ¥57,894,104.33 in the previous period, indicating an increase of 12.93%[38]. - Net profit for the current period was ¥46,109,690.65, slightly up from ¥45,978,682.20, showing a growth of 0.28%[40]. - Total profit for the current period was ¥63,214,112.02, an increase from ¥57,596,421.72, marking a growth of 9.03%[40]. Cash Flow and Assets - The net cash flow from operating activities was negative at approximately -¥17.53 million, a decline of 137.05% compared to ¥47.32 million in the previous year[9]. - Cash and cash equivalents at the end of the period totaled ¥239,120,554.50, down from ¥347,759,764.89, a decrease of 31.19%[44]. - The company's current assets decreased to CNY 2,077,881,082.82 from CNY 2,238,419,591.84 at the beginning of the year, reflecting a decline of approximately 7.2%[35]. - The company's cash and cash equivalents dropped to CNY 371,760,382.77 from CNY 633,520,126.20, representing a decrease of about 41.2%[35]. - The total liabilities decreased to CNY 1,044,536,229.84 from CNY 1,260,278,114.05, indicating a reduction of approximately 17.1%[36]. - Total assets at the end of the reporting period were approximately ¥2.47 billion, down 6.43% from ¥2.64 billion at the end of the previous year[5]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 55,753[11]. - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 23.82% of shares, totaling 141,955,475 shares, with 69,607,360 shares frozen[12]. - The second-largest shareholder, Peking University Health Management Co., Ltd., holds 11.80% of shares, totaling 70,328,949 shares[12]. - The major shareholder, Composite Group, has reduced its holdings by 2,980,200 shares, accounting for 0.5% of the total share capital[22]. - Composite Group's cumulative reduction of shares reached 1% from November 10, 2022, to May 19, 2023[24]. - Composite Group has passively reduced its holdings by 5,959,700 shares, representing 1% of the total share capital[25]. - Composite Group's passive reduction plan has been completed, and 1,600,000 shares are at risk of being executed due to a legal dispute[28]. Research and Development - Research and development expenses increased by 120.79% to approximately ¥13.82 million compared to ¥6.26 million in the same period last year[9]. - The company plans to continue investing in research and development projects to enhance its product offerings and market position[9]. - Research and development expenses increased significantly to ¥13,816,597.37 from ¥6,257,913.86, representing a rise of 120.66%[38]. Regulatory and Market Activities - The company received approval from the National Medical Products Administration for the drug supplement application for injectable cefotaxime sodium, passing the consistency evaluation of generic drug quality and efficacy[14]. - The company participated in the bidding for the eighth batch of national centralized drug procurement, with products including oxytetracycline injection and compound sulfamethoxazole tablets expected to be selected[17]. - The company obtained a drug registration certificate for citric acid tamsulosin tablets, meeting the requirements for drug registration[17]. - The company is under continuous supervision by China International Capital Corporation regarding its acquisition of Beijing University Pharmaceutical Co., Ltd.[31]. Profit Distribution and Financial Decisions - The company decided not to distribute profits for the fiscal year 2022, with no cash dividends or stock bonuses issued[20]. - The company has resolved the risk related to the financing guarantee provided for Beijing Medical Industry Group Co., Ltd. at Nanjing Bank[20]. - The company terminated the project development of Succinic Acid Qugleritine due to lack of substantial progress since its initiation in 2018[21]. Financial Adjustments and Accounting - The company reported a significant increase in credit impairment losses, which rose to ¥7,129,286.02 from ¥1,499,493.96, an increase of 376.73%[38]. - Deferred tax assets increased from 21,705,215.70 to 22,407,387.67 after new accounting standards adjustment, reflecting an increase of 3.22%[45]. - Unappropriated profits rose from 530,931,291.59 to 531,210,240.99, showing an increase of 0.05% due to the new accounting standards[45]. - Income tax expenses adjusted from 11,826,184.94 to 11,617,739.52, resulting in a decrease of 1.77% after the new accounting standards[45]. - The company's third-quarter report was not audited, indicating potential implications for financial reliability[46].